Search

Your search keyword '"Ntinginya, Nyanda E."' showing total 149 results
Start Over Author "Ntinginya, Nyanda E."
149 results on '"Ntinginya, Nyanda E."'

1. Lessons from enriching Tanzania’s clinical research ethics clinical trials oversight and pharmacovigilance through the ASCEND project

Author

Fimbo, Adam, Mwalwisi, Yona H., Matiko, Damas, Mlugu, Eulambius M., Gedi, Emmanuel Masunga, Oriyo, Ndekya M., Mmbaga, Blandina T., Ntinginya, Nyanda E., Sabiiti, Wilber, Mcharo, Ruby, Masemo, Ame, Chambiri, Sunzy M., Lichanda, Bora, Ally, Mayassa, Simai, Burhani, Kaale, Eliangiringa, Mnkugwe, Rajabu Hussein, Kunambi, Peter P., Munishi, Castory, Gotora, Goodluck B., and Mwamwitwa, Kissa

Published
2024
Full Text
View/download PDF

2. Effect of seven anti-tuberculosis treatment regimens on sputum microbiome: a retrospective analysis of the HIGHRIF study 2 and PanACEA MAMS-TB clinical trials

Author

Musisi, Emmanuel, Mtafya, Bariki, Ntinginya, Nyanda E., Heinrich, Norbert, Kibiki, Gibson S., Hoelscher, Michael, Boeree, Martin, Gillespie, Stephen, Sabiiti, Wilber, Sloan, Derek, Hoffmann, Larissa, Noreña, Ivan, Lutchmun, Wandini, Dreisbach, Julia, Demel, Petra Gross, Kelly, Andrea, Brake, Lindsey te, Svensson, Elin, Aarnoutse, Rob, Honeyborne, Isobella, Wildner, Leticia Muraro, Hunt, Robert, McHugh, Timothy D., Nunn, Andrew J, Phillips, Patrick P.J., Gong, Xue, Dawson, Rodney, Narunsky, Kim, Diacon, Andreas, de Jager, Veronique, Friedrich, Sven, Sanne, Ian, Rassool, Mohammed, Mangu, Chacha, Manyama, Christina, Sabi, Issa, Minja, Lilian T., Mhimbira, Francis, Mbeya, Benno, Sasamalo, Mohamed, Reither, Klaus, Jugheli, Levan, Sam, Noel, Semvua, Hadija, Mpagama, Stellah, Liyoyo, Alphonce, Mmbaga, Blandina T., Adegbite, Bayode Romeo, Adegnika, Ayola Akim, Grobusch, Martin Peter, Grobusch, Martin P., Kirenga, Bruce, Ssengooba, Willy, Joloba, Moses, Khosa, Celso, Massango, Isabel, Azam, Khalide, Jani, Ilesh, Nliwasa, Mariott, Twabi, Hussein Hassan, Mukoka, Madalo, Msefula, Chisomo L., Wyness, Adam, Eldirdiri, Sahar, Dombay, Evelin, Ntinginya, Nyanda E, Kibiki, Gibson S, and Gillespie, Stephen H

Published
2023
Full Text
View/download PDF

3. Unravelling patient pathways in the context of antibacterial resistance in East Africa

Author

Keenan, Katherine, Fredricks, Kathryn J., Al Ahad, Mary Abed, Neema, Stella, Mwanga, Joseph R., Kesby, Mike, Mushi, Martha F., Aduda, Annette, Green, Dominique L., Lynch, Andy G., Huque, Sarah I., Mmbaga, Blandina T., Worthington, Hannah, Kansiime, Catherine, Olamijuwon, Emmanuel, Ntinginya, Nyanda E., Loza, Olga, Bazira, Joel, Maldonado-Barragán, Antonio, Smith, VAnne, Decano, Arun Gonzales, Njeru, John Mwaniki, Sandeman, Alison, Stelling, John, Elliott, Alison, Aanensen, David, Gillespie, Stephen H., Kibiki, Gibson, Sabiiti, Wilber, Sloan, Derek J., Asiimwe, Benon B., Kiiru, John, Mshana, Stephen E., and Holden, Matthew T. G.

Published
2023
Full Text
View/download PDF

4. Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-income countries

Author

Baard, Cynthia Biddle, Munro, Jacinta Diane, Prins, Margaretha, Benzi, Nolufefe, Bateman, Linda Claire, Ryan, Ashleigh, Booi, Kutala, Paulo, Nezisa, Heydenrych, Anthenette, Petersen, Wonita, Brookes, Raquel, Mento, Michele, Centner, Chad, Dalgarno, Craig, Rieß, Friedrich, Mutuku, Sarah, Saathoff, Elmar, Held, Kathrin, Ninan, Marilyn Mary, Chacko, Anila, Kumari, Ramya, Dhanabhagyam, R, Muniswamy, Nithya, Nicol, Marc P, Mtafya, Bariki, Mwambola, Harieth, Manyama, Christina, Mahiga, Hellen, Sichone, Emanuel, Sudi, Lwitiho, Maueia, Cremildo, Madeira, Carla, Cambuie, Justina, Ribeiro, Jorge, Chiume, Lingstone, Mnyanga, Alice, Sikwese, Tionge, Masakasa, Happy, Kachere, Diana, Kosaka, Masheck, Niemann, Stefan, Chegou, Novel, Horn, Lyn, Olbrich, Laura, Verghese, Valsan P, Franckling-Smith, Zoe, Sabi, Issa, Ntinginya, Nyanda E, Mfinanga, Alfred, Banze, Denise, Viegas, Sofia, Khosa, Celso, Semphere, Robina, Nliwasa, Marriott, McHugh, Timothy D, Larsson, Leyla, Razid, Alia, Song, Rinn, Corbett, Elizabeth L, Nabeta, Pamela, Trollip, Andre, Graham, Stephen M, Hoelscher, Michael, Geldmacher, Christof, Zar, Heather J, Michael, Joy Sarojini, and Heinrich, Norbert

Published
2024
Full Text
View/download PDF

5. Mycobactericidal Effects of Different Regimens Measured by Molecular Bacterial Load Assay among People Treated for Multidrug-Resistant Tuberculosis in Tanzania

Author

Mbelele, Peter M, Mpolya, Emmanuel A, Sauli, Elingarami, Mtafya, Bariki, Ntinginya, Nyanda E, Addo, Kennedy K, Kreppel, Katharina, Mfinanga, Sayoki, Phillips, Patrick PJ, Gillespie, Stephen H, Heysell, Scott K, Sabiiti, Wilber, and Mpagama, Stellah G

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Emerging Infectious Diseases, Antimicrobial Resistance, Infectious Diseases, Rare Diseases, Tuberculosis, Orphan Drug, Prevention, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Infection, Good Health and Well Being, Antitubercular Agents, Bacterial Load, Diarylquinolines, Humans, Mycobacterium tuberculosis, RNA, Ribosomal, 16S, Tanzania, Tuberculosis, Multidrug-Resistant, Kibong'oto, MDR-TB treatment regimens, molecular bacterial load assay, multidrug-resistant TB, mycobactericidal effects, all-oral bedaquiline regimen, injectable aminoglycoside regimen, Biological Sciences, Agricultural and Veterinary Sciences, Medical and Health Sciences, Microbiology, Clinical sciences, Medical microbiology
Abstract

Rifampin or multidrug-resistant tuberculosis (RR/MDR-TB) treatment has largely transitioned to regimens free of the injectable aminoglycoside component, despite the drug class' purported bactericidal activity early in treatment. We tested whether Mycobacterium tuberculosis killing rates measured by tuberculosis molecular bacterial load assay (TB-MBLA) in sputa correlate with composition of the RR/MDR-TB regimen. Serial sputa were collected from patients with RR/MDR- and drug-sensitive TB at days 0, 3, 7, and 14, and then monthly for 4 months of anti-TB treatment. TB-MBLA was used to quantify viable M. tuberculosis 16S rRNA in sputum for estimation of colony forming units per ml (eCFU/ml). M. tuberculosis killing rates were compared among regimens using nonlinear-mixed-effects modeling of repeated measures. Thirty-seven patients produced 296 serial sputa and received treatment as follows: 13 patients received an injectable bedaquiline-free reference regimen, 9 received an injectable bedaquiline-containing regimen, 8 received an all-oral bedaquiline-based regimen, and 7 patients were treated for drug-sensitive TB with conventional rifampin/isoniazid/pyrazinamide/ethambutol (RHZE). Compared to the adjusted M. tuberculosis killing of -0.17 (95% confidence interval [CI] -0.23 to -0.12) for the injectable bedaquiline-free reference regimen, the killing rates were -0.62 (95% CI -1.05 to -0.20) log10 eCFU/ml for the injectable bedaquiline-containing regimen (P = 0.019), -0.35 (95% CI -0.65 to -0.13) log10 eCFU/ml for the all-oral bedaquiline-based regimen (P = 0.054), and -0.29 (95% CI -0.78 to +0.22) log10 eCFU/ml for the RHZE regimen (P = 0.332). Thus, M. tuberculosis killing rates from sputa were higher among patients who received bedaquiline but were further improved with the addition of an injectable aminoglycoside.

Published
2021

6. The role of multidimensional poverty in antibiotic misuse: a mixed-methods study of self-medication and non-adherence in Kenya, Tanzania, and Uganda

Author

Green, Dominique L, Keenan, Katherine, Fredricks, Kathryn J, Huque, Sarah I, Mushi, Martha F, Kansiime, Catherine, Asiimwe, Benon, Kiiru, John, Mshana, Stephen E, Neema, Stella, Mwanga, Joseph R, Kesby, Mike, Lynch, Andy G, Worthington, Hannah, Olamijuwon, Emmanuel, Abed Al Ahad, Mary, Aduda, Annette, Njeru, John Mwaniki, Mmbaga, Blandina T, Bazira, Joel, Sandeman, Alison, Stelling, John, Gillespie, Stephen H, Kibiki, Gibson, Sabiiti, Wilber, Sloan, Derek J, Holden, Matthew T G, Smith, V Anne, Decano, Arun Gonzales, Maldonado-Barragán, Antonio, Aanensen, David, Ntinginya, Nyanda E, Elliott, Alison, and Clarkson, Madeleine

Published
2023
Full Text
View/download PDF

7. Non-prescribed antibiotic dispensing practices for symptoms of urinary tract infection in community pharmacies and accredited drug dispensing outlets in Tanzania: a simulated clients approach

Author

Ndaki, Pendo M., Mushi, Martha F., Mwanga, Joseph R., Konje, Eveline T., Mugassa, Stella, Manyiri, Msilikale W., Mwita, Stanley M., Ntinginya, Nyanda E., Mmbaga, Blandina T., Keenan, Katherine, Sabiiti, Wilber, Kesby, Mike, Benitez-Paez, Fernando, Sandeman, Alison, Holden, Matthew T. G., and Mshana, Stephen E.

Published
2022
Full Text
View/download PDF

8. Detection of Bombali Virus in a Mops condylurus Bat in Kyela, Tanzania.

Author

Düx, Ariane, Lwitiho, Sudi E., Ayouba, Ahidjo, Röthemeier, Caroline, Merkel, Kevin, Weiss, Sabrina, Thaurignac, Guillaume, Lander, Angelika, Kouadio, Leonce, Nowak, Kathrin, Corman, Victor, Drosten, Christian, Couacy-Hymann, Emmanuel, Krüger, Detlev H., Kurth, Andreas, Calvignac-Spencer, Sébastien, Peeters, Martine, Ntinginya, Nyanda E., Leendertz, Fabian H., and Mangu, Chacha

Abstract

Bombali virus (BOMV) is a novel Orthoebolavirus that has been detected in free-tailed bats in Sierra Leone, Guinea, Kenya, and Mozambique. We screened our collection of 349 free-tailed bat lungs collected in Côte d'Ivoire and Tanzania for BOMV RNA and tested 228 bat blood samples for BOMV antibodies. We did not detect BOMV-specific antibodies but found BOMV RNA in a Mops condylurus bat from Tanzania, marking the first detection of an ebolavirus in this country. Our findings further expand the geographic range of BOMV and support M. condylurus' role as a natural BOMV host. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Perceived access to social support during and after TB treatment in Mbeya and Songwe regions, Tanzania: perspectives from TB patients and survivors set against health care providers.

Author

Kilima, Stella P., Mubyazi, Godfrey M., Moolla, Aneesa, Ntinginya, Nyanda E., Sabi, Issa, Mwanyonga, Simeon P., and Evans, Denise

Subjects
TUBERCULOSIS treatment, PATIENT compliance, PSYCHOLOGICAL resilience, HEALTH self-care, MEDICAL care use, QUALITATIVE research, ENDOWMENTS, INTERVIEWING, JUDGMENT sampling, HELP-seeking behavior, PSYCHOLOGICAL adaptation, EMOTIONS, FAMILY relations, CONCEPTUAL structures, SOCIAL support, DRUGS, TUBERCULOSIS, PATIENTS' attitudes, MEDICAL care costs, SOCIAL isolation
Abstract

Introduction: Pulmonary tuberculosis (PTB) remains a life-threatening disease in Tanzania, with negative physical, financial, economic and psychosocial consequences to individuals and the society. It mainly lowers the quality of life of patients, survivors and their families, especially those in the poorest and socially deprived categories. Objectives: To report and discuss a qualitative study that assessed the nature of social support desired and received by PTB patients and survivors. Participants were given a chance to share their experiences and their perceptions on whether the social support they desired had an impact on their treatmentseeking behaviour and treatment adherence. Methods: Face-to-face interviews were conducted with the three aforementioned groups, purposively selected at a TB clinic between October 2020 and March 2021. The questions covered topics related to the types of social support desired and the sources of support during and after treatment, if any. Interviews were concluded until no new information was obtained. Data analysis was facilitated using NVivo 12 software. Results: Participants pointed out a need for psychosocial, financial, and material support during and after treatment. However, they sometimes miss support from family/household members or the rest of the community. Because of this experience, they lived with difficulties, facing hardships when required to pay out of pocket for transport during the care-seeking. Survivors testified experience of a denial of support by even their close relatives who regarded them as no longer needing it after recovering. Patients and survivors also reported experience of social isolation as they were believed able to transmit PTB infections. Limited psychological support at the contacted TB clinics was another experience reported. TB clinic staff's experiences confirmed almost all the experiences shared by their clients. With limited support, resilience and self-care were identified as key mechanisms for coping. Conclusion: Complete recovery from PTB is possible, but reverting to a normal life is difficult without social support. Policies and programs need to increase opportunities for social support for TB patients and survivors. Doing so is likely to improve TB-related treatment, care-seeking practices, and adherence. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Prevalence and Trend of Oral and Maxillofacial Injuries among Patients Attended at Mbeya Zonal Referral Hospital, Tanzania: A four - years retrospective study.

Author

Birigi, Msafiri Leonard, Lwilla, Anange Fred, Olomi, Willyhelmina, Kasambala, Ibrahim, Mwamgunda, Bogias Fidelis, Mwaisango, Zawadi, Nyatu, Flaviana Joseph, Nzobo, Baraka Jeremiah, Mugonzibwa, Emeria A., Mweya, Clement N., Mbwanji, Godlove Fred, Ntinginya, Nyanda E., and Kalyanyama, Boniface

Abstract

Background: Oral and maxillofacial injuries pose a significant public health burden, but data on their patterns and prevalence is lacking in many developing countries like Tanzania. This study aimed to establish baseline data on these injuries' prevalence, patterns, and associated factors among Mbeya Zonal Referral Hospital (MZRH) patients. Methods: A retrospective assessment of electronic medical records was conducted for all patients presenting with oral and maxillofacial trauma at MZRH between January 2019 and December 2022. Data on demographics, injury types, and admission status were extracted. Descriptive statistics and logistic regression models were used for analysis. Results: Of 608 patients, 82.9% were males, and the median age was 28. Fractures of the mandible (53%) were most common, followed by malar/maxillary fractures (34%) and soft tissue injuries (12%). Malar/maxillary fractures had the highest odds of admission. Males had 1.84 times higher odds of malar/maxillary fractures than females. The 0-17 age group had higher odds of soft tissue injuries than older ages. Patients aged 18-34 years had twice the odds of mandibular fractures versus the youngest group. Conclusion: Oral and maxillofacial injuries predominantly affected young adult males in this region. Mandibular fractures were most common, but malar/maxillary fractures required more admission. Age and gender were associated with anatomical patterns of injuries. The findings highlight the need for preventive strategies and management protocols tailored to regional epidemiology. [ABSTRACT FROM AUTHOR]

Published
2024

11. PA-496 Bridging the gap: training needs assessment for clinical trials assessors and inspectors and implementation of targeted capacity building in Tanzania

Author

Mwamwitwa, Kissa W, primary, Fimbo, Adam M, additional, Munishi, Castory, additional, Mwalwisi, Yonah, additional, Malaba, Paul, additional, Chambiri, Sunzy, additional, Maganga, Aisha, additional, Ally, Mayassa S, additional, Simai, Burhani O, additional, Oriyo, Ndekya, additional, Sabitii, Wilber, additional, Mmbaga, Blandina, additional, Mloka, Doreen, additional, Ntinginya, Nyanda E, additional, and Kaale, Eliangiringa, additional

Published
2023
Full Text
View/download PDF

12. Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-income countries

Author

Olbrich, Laura, primary, Verghese, Valsan P, additional, Franckling-Smith, Zoe, additional, Sabi, Issa, additional, Ntinginya, Nyanda E, additional, Mfinanga, Alfred, additional, Banze, Denise, additional, Viegas, Sofia, additional, Khosa, Celso, additional, Semphere, Robina, additional, Nliwasa, Marriott, additional, McHugh, Timothy D, additional, Larsson, Leyla, additional, Razid, Alia, additional, Song, Rinn, additional, Corbett, Elizabeth L, additional, Nabeta, Pamela, additional, Trollip, Andre, additional, Graham, Stephen M, additional, Hoelscher, Michael, additional, Geldmacher, Christof, additional, Zar, Heather J, additional, Michael, Joy Sarojini, additional, Heinrich, Norbert, additional, Baard, Cynthia Biddle, additional, Munro, Jacinta Diane, additional, Prins, Margaretha, additional, Benzi, Nolufefe, additional, Bateman, Linda Claire, additional, Ryan, Ashleigh, additional, Booi, Kutala, additional, Paulo, Nezisa, additional, Heydenrych, Anthenette, additional, Petersen, Wonita, additional, Brookes, Raquel, additional, Mento, Michele, additional, Centner, Chad, additional, Dalgarno, Craig, additional, Rieß, Friedrich, additional, Mutuku, Sarah, additional, Saathoff, Elmar, additional, Held, Kathrin, additional, Ninan, Marilyn Mary, additional, Chacko, Anila, additional, Kumari, Ramya, additional, Dhanabhagyam, R, additional, Muniswamy, Nithya, additional, Nicol, Marc P, additional, Mtafya, Bariki, additional, Mwambola, Harieth, additional, Manyama, Christina, additional, Mahiga, Hellen, additional, Sichone, Emanuel, additional, Sudi, Lwitiho, additional, Maueia, Cremildo, additional, Madeira, Carla, additional, Cambuie, Justina, additional, Ribeiro, Jorge, additional, Chiume, Lingstone, additional, Mnyanga, Alice, additional, Sikwese, Tionge, additional, Masakasa, Happy, additional, Kachere, Diana, additional, Kosaka, Masheck, additional, Niemann, Stefan, additional, Chegou, Novel, additional, and Horn, Lyn, additional

Published
2023
Full Text
View/download PDF

13. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial

Author

Tweed, Conor D, Dawson, Rodney, Burger, Divan A, Conradie, Almari, Crook, Angela M, Mendel, Carl M, Conradie, Francesca, Diacon, Andreas H, Ntinginya, Nyanda E, Everitt, Daniel E, Haraka, Frederick, Li, Mengchun, van Niekerk, Christo H, Okwera, Alphonse, Rassool, Mohammed S, Reither, Klaus, Sebe, Modulakgotla A, Staples, Suzanne, Variava, Ebrahim, and Spigelman, Melvin

Published
2019
Full Text
View/download PDF

14. Implementing Innovative Approaches to Improve Health Care Delivery Systems for Integrating Communicable and Non-Communicable Diseases Using Tuberculosis and Diabetes as a Model in Tanzania

Author

Mpagama, Stellah G., primary, Byashalira, Kenneth C., additional, Chamba, Nyasatu G., additional, Heysell, Scott K., additional, Alimohamed, Mohamed Z., additional, Shayo, Pendomartha J., additional, Kalolo, Albino, additional, Chongolo, Anna M., additional, Gitige, Catherine G., additional, Mmbaga, Blandina T., additional, Ntinginya, Nyanda E., additional, Alffenaar, Jan-Willem C., additional, Bygbjerg, Ib C., additional, Lillebaek, Troels, additional, Christensen, Dirk L., additional, and Ramaiya, Kaushik L., additional

Published
2023
Full Text
View/download PDF

16. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

Author

Boeree, Martin J, Heinrich, Norbert, Aarnoutse, Rob, Diacon, Andreas H, Dawson, Rodney, Rehal, Sunita, Kibiki, Gibson S, Churchyard, Gavin, Sanne, Ian, Ntinginya, Nyanda E, Minja, Lilian T, Hunt, Robert D, Charalambous, Salome, Hanekom, Madeleine, Semvua, Hadija H, Mpagama, Stellah G, Manyama, Christina, Mtafya, Bariki, Reither, Klaus, Wallis, Robert S, Venter, Amour, Narunsky, Kim, Mekota, Anka, Henne, Sonja, Colbers, Angela, van Balen, Georgette Plemper, Gillespie, Stephen H, Phillips, Patrick P J, and Hoelscher, Michael

Published
2017
Full Text
View/download PDF

18. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis

Author

Dawson, Rodney, Diacon, Andreas H, Everitt, Daniel, van Niekerk, Christo, Donald, Peter R, Burger, Divan A, Schall, Robert, Spigelman, Melvin, Conradie, Almari, Eisenach, Kathleen, Venter, Amour, Ive, Prudence, Page-Shipp, Liesl, Variava, Ebrahim, Reither, Klaus, Ntinginya, Nyanda E, Pym, Alexander, von Groote-Bidlingmaier, Florian, and Mendel, Carl M

Published
2015
Full Text
View/download PDF

19. Experiences and perceptions of participants on the pathway towards clinical management of dual tuberculosis and diabetes mellitus in Tanzania

Author

Chamba, Nyasatu G., primary, Byashalira, Kenneth C., additional, Christensen, Dirk L., additional, Ramaiya, Kaushik L., additional, Kapyolo, Eliakimu P., additional, Shayo, PendoMartha J., additional, Lillebaek, Troels, additional, Ntinginya, Nyanda E., additional, Mmbaga, Blandina T., additional, Bygbjerg, Ib C., additional, Mpagama, Stellah G., additional, and Manongi, Rachel N., additional

Published
2022
Full Text
View/download PDF

21. Unravelling patient pathways in the context of antibacterial resistance in East Africa

Author

Keenan, Katherine, primary, Fredricks, Kathryn J., additional, Ahad, Mary Abed Al, additional, Neema, Stella, additional, Mwanga, Joseph R., additional, Kesby, Mike, additional, Mushi, Martha F., additional, Aduda, Annette, additional, Green, Dominique L., additional, Lynch, Andy G., additional, Huque, Sarah I., additional, Mmbaga, Blandina T., additional, Worthington, Hannah, additional, Kansiime, Catherine, additional, Olamijuwon, Emmanuel, additional, Ntinginya, Nyanda E., additional, Loza, Olga, additional, Bazira, Joel, additional, Maldonado-Barragán, Antonio, additional, Smith, V Anne, additional, Decano, Arun Gonzales, additional, Mwaniki, John Njeru, additional, Sandeman, Alison, additional, Stelling, John, additional, Elliott, Alison, additional, Aanensen, David, additional, Gillespie, Stephen H., additional, Kibiki, Gibson, additional, Sabiiti, Wilber, additional, Sloan, Derek J., additional, Asiimwe, Benon B., additional, Kiiru, John, additional, Mshana, Stephen E., additional, Holden, Matthew T. G., additional, and Consortium, HATUA, additional

Published
2022
Full Text
View/download PDF

22. Rapid and Accurate Diagnosis of Pediatric Tuberculosis Disease: A Diagnostic Accuracy Study for Pediatric Tuberculosis.

Author

Olbrich, Laura, Nliwasa, Marriott, Sabi, Issa, Ntinginya, Nyanda E., Khosa, Celso, Banze, Denise, Corbett, Elizabeth L., Semphere, Robina, Verghese, Valsan P., Michael, Joy Sarojini, Graham, Stephen M., Egere, Uzochukwu, Schaaf, H. Simon, Morrison, Julie, McHugh, Timothy D., Song, Rinn, Nabeta, Pamela, Trollip, Andre, Geldmacher, Christof, and Hoelscher, Michael

Published
2023
Full Text
View/download PDF

23. Where can Tanzania health system integrate clinical management of patients with dual tuberculosis and diabetes mellitus? A cross-sectional survey at varying levels of health facilities

Author

Chamba, Nyasatu G., primary, Byashalira, Kenneth C., additional, Shayo, PendoMartha J., additional, Ramaiya, Kaushik L., additional, Manongi, Rachel N., additional, Daud, Peter, additional, Mmbaga, Blandina T., additional, Ntinginya, Nyanda E., additional, Lillebæk, Troels, additional, Bygbjerg, Ib C., additional, Christensen, Dirk L., additional, and Mpagama, Stellah G., additional

Published
2022
Full Text
View/download PDF

24. Additional file 1 of Non-prescribed antibiotic dispensing practices for symptoms of urinary tract infection in community pharmacies and accredited drug dispensing outlets in Tanzania: a simulated clients approach

Author

Ndaki, Pendo M., Mushi, Martha F., Mwanga, Joseph R., Konje, Eveline T., Mugassa, Stella, Manyiri, Msilikale W., Mwita, Stanley M., Ntinginya, Nyanda E., Mmbaga, Blandina T., Keenan, Katherine, Sabiiti, Wilber, Kesby, Mike, Benitez-Paez, Fernando, Sandeman, Alison, Holden, Matthew T. G., and Mshana, Stephen E.

Abstract

Additional file 1.

Published
2022
Full Text
View/download PDF

25. Sub-Lineage Specific Phenolic Glycolipid Patterns in the Mycobacterium tuberculosis Complex Lineage 1

Author

Gisch, Nicolas, primary, Utpatel, Christian, additional, Gronbach, Lisa M., additional, Kohl, Thomas A., additional, Schombel, Ursula, additional, Malm, Sven, additional, Dobos, Karen M., additional, Hesser, Danny C., additional, Diel, Roland, additional, Götsch, Udo, additional, Gerdes, Silke, additional, Shuaib, Yassir A., additional, Ntinginya, Nyanda E., additional, Khosa, Celso, additional, Viegas, Sofia, additional, Kerubo, Glennah, additional, Ali, Solomon, additional, Al-Hajoj, Sahal A., additional, Ndung’u, Perpetual W., additional, Rachow, Andrea, additional, Hoelscher, Michael, additional, Maurer, Florian P., additional, Schwudke, Dominik, additional, Niemann, Stefan, additional, Reiling, Norbert, additional, and Homolka, Susanne, additional

Published
2022
Full Text
View/download PDF

26. Non-prescribed antibiotic dispensing practices for symptoms of urinary tract infection in community pharmacies and accredited drug dispensing outlets in Tanzania. A simulated clients approach

Author

Ndaki, Pendo M., primary, Mushi, Martha F., additional, Mwanga, Joseph R., additional, Konje, Eveline T., additional, Mugassa, Stella, additional, Manyiri, Msilikale W., additional, Mwita, Stanley M., additional, Ntinginya, Nyanda E., additional, Mmbaga, Blandina T., additional, Keenan, Katherine, additional, Sabiiti, Wilber, additional, Kesby, Mike, additional, Sandeman, Alison, additional, -Paez, Fernando B., additional, Holden, Matthew T.G., additional, and Mshana, Stephen E., additional

Published
2022
Full Text
View/download PDF

27. The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations

Author

Bowness, Ruth, Boeree, Martin J., Aarnoutse, Rob, Dawson, Rodney, Diacon, Andreas, Mangu, Chacha, Heinrich, Norbert, Ntinginya, Nyanda E., Kohlenberg, Anke, Mtafya, Bariki, Phillips, Patrick P. J., Rachow, Andrea, Plemper van Balen, Georgette, and Gillespie, Stephen H.

Published
2015
Full Text
View/download PDF

28. Impact of early diagnosis of impaired glucose regulation in tuberculosis: Comparison of clinical outcomes in people with tuberculosis in Tanzania.

Author

Byashalira, Kenneth C., Chamba, Nyasatu G., Alkabab, Yosra, Mbelele, Peter M., Mpolya, Emmanuel A., Ntinginya, Nyanda E., Shayo, PendoMartha J., Ramaiya, Kaushik L., Lillebaek, Troels, Heysell, Scott K., Mmbaga, Blandina T., Bygbjerg, Ib C., Mpagama, Stellah G., Christensen, Dirk L., and ADEPT consortium

Subjects
HIV infection epidemiology, HIV infection complications, TUBERCULOSIS diagnosis, DRUG therapy for tuberculosis, TUBERCULOSIS complications, HYPERGLYCEMIA, DIABETES, GLUCOSE, EARLY diagnosis, LONGITUDINAL method
Abstract

Objective: Diabetes mellitus (DM) has been known to compromise tuberculosis (TB) treatment outcomes. Association data are limited for early hyperglycaemia detection and TB treatment outcomes. Thus, we assessed treatment outcomes including time to sputum conversion and death in TB participants with or without hyperglycaemia.Methods: A prospective cohort study recruited TB participants receiving anti-TB treatment at health facilities in Tanzania between October 2019 and September 2020. Hyperglycaemia was defined as having pre-existing DM or pre-treatment random blood glucose of ≥7.8 mmol/L, in combination categorised as impaired glucose regulation (IGR). Those with IGR were further screened for hyperglycaemia severity using glycated haemoglobin. In case of unknown status, participants were tested for HIV. Time to death was determined at 6 months of TB treatment.Results: Of 1344 participants, 187 (13.9%) had IGR, of whom 44 (23.5%) were HIV co-infected. Overall treatment success was 1206 (89.7%), and was similar among participants with or without IGR (p > 0.05). Time to death for participants with and without IGR was 18 versus 28 days (p = 0.870), respectively. Age ≥ 40 years (p = 0.038), bacteriological positive (p = 0.039), HIV (p = 0.009), or recurrent TB (p = 0.017) predicted death or treatment success during TB treatment in adjusted multivariable models.Conclusion: IGR did not influence clinical outcomes in TB patients with or without IGR in a programme of early IGR diagnosis and integration TB, HIV and DM care. Early detection and co-management of multi-morbidities among people diagnosed with TB may reduce likelihood of poor treatment outcomes in a programmatic setting. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

29. Dispensing Antibiotics without Prescription at Community Pharmacies and Accredited Drug Dispensing Outlets in Tanzania: A Cross-Sectional Study

Author

Ndaki, Pendo M., Mushi, Martha F., Mwanga, Joseph R., Konje, Eveline T., Ntinginya, Nyanda E., Mmbaga, Blandina T., Keenan, Katherine, Sabiiti, Wilber, Kesby, Mike, Benitez-Paez, Fernando, Sandeman, Alison, Holden, Matthew T. G., Mshana, Stephen E., Consortium, HATUA Consortium HATUA, Medical Research Council, University of St Andrews. Geographies of Sustainability, Society, Inequalities and Possibilities, University of St Andrews. Population and Health Research, University of St Andrews. School of Geography & Sustainable Development, University of St Andrews. Infection and Global Health Division, University of St Andrews. School of Medicine, University of St Andrews. Biomedical Sciences Research Complex, and University of St Andrews. St Andrews Bioinformatics Unit

Subjects
Microbiology (medical), RM, medicine.medical_specialty, antibiotic resistance, Antibiotic resistance, Cross-sectional study, Pharmacy, E-DAS, RM1-950, dispensing practice, Biochemistry, Microbiology, Prescription, Article, Drug dispensing, antibiotic, medicine, Pharmacology (medical), General Pharmacology, Toxicology and Pharmaceutics, Medical prescription, Accreditation, prescription, Community pharmacies, Government, biology, business.industry, Antibiotic, QR Microbiology, biology.organism_classification, RM Therapeutics. Pharmacology, QR, Infectious Diseases, Tanzania, Family medicine, Therapeutics. Pharmacology, business, Dispensing practice
Abstract

This study was part of the larger 3-country Holistic Approach to Unravel Antibacterial Resistance in East Africa (HATUA) project funded by the National Institute for Health Research, Medical Research Council and the Department of Health and Social Care, Award (MR/S004785/1). Worldwide, antimicrobial resistance is increasing rapidly and is highly associated with misuse of antimicrobials. The HATUA study (a broader 3-country study) investigated the antibiotic dispensing practices of pharmaceutical providers to clients, particularly the propensity to dispense without prescription. A cross-sectional study using a ‘mystery client’ method was conducted in 1,148 community pharmacies and accredited drugs dispensing outlets (ADDO) in Mwanza (n = 612), Mbeya (n = 304) and Kilimanjaro (n = 232) in Tanzania. Mystery clients asked directly for amoxicillin, had no prescription to present, did not discuss symptoms unless asked [when asked reported UTI-like symptoms] and attempted to buy a half course. Dispensing of amoxicillin without prescription was common [88.2, 95%CI 86.3%–89.9%], across all three regions. Further-more, a majority of outlets sold a half course of amoxicillin without prescription: Mwanza (98%), Mbeya (99%) and Kilimanjaro (98%). Generally, most providers in all three regions dispensed amoxicillin on demand, without asking the client any questions with [Chi2 = 11.8851 and p-value = 0.003]. In Mbeya and Kilimanjaro, providers in ADDOs were more likely to do this than those in pharmacies but no difference was observed in Mwanza. While the Tanzanian government has laws, regulations and guidelines that prohibit antibiotic dispensing without prescription, our study suggests non-compliance by drug providers. Enforcement, surveillance, and the provision of continuing education on dispensing practices is recommended, particularly for ADDO providers. Publisher PDF

Published
2021

30. Regional Variation of Extended-Spectrum Beta-Lactamase (ESBL)-Producing Enterobacterales, Fluoroquinolone-Resistant Salmonella enterica and Methicillin-Resistant Staphylococcus aureus Among Febrile Patients in Sub-Saharan Africa

Author

Moirongo, Rehema Moraa, primary, Lorenz, Eva, additional, Ntinginya, Nyanda E., additional, Dekker, Denise, additional, Fernandes, José, additional, Held, Jana, additional, Lamshöft, Maike, additional, Schaumburg, Frieder, additional, Mangu, Chacha, additional, Sudi, Lwitiho, additional, Sie, Ali, additional, Souares, Aurelia, additional, Heinrich, Norbert, additional, Wieser, Andreas, additional, Mordmüller, Benjamin, additional, Owusu-Dabo, Ellis, additional, Adegnika, Akim Ayola, additional, Coulibaly, Boubacar, additional, May, Jürgen, additional, and Eibach, Daniel, additional

Published
2020
Full Text
View/download PDF

31. Deploying a novel tuberculosis molecular bacterial load assay to assess the elimination rate ofMycobacterium tuberculosisin patients with multidrug-resistant tuberculosis in Tanzania

Author

Mbelele, Peter M., primary, Mpolya, Emmanuel A., additional, Sauli, Elingarami, additional, Mtafya, Bariki, additional, Ntinginya, Nyanda E., additional, Addo, Kennedy K., additional, Kreppel, Katharina, additional, Mfinanga, Sayoki, additional, Phillips, Patrick P.J., additional, Gillespie, Stephen H., additional, Heysell, Scott K., additional, Sabiiti, Wilber, additional, and Mpagama, Stellah G., additional

Published
2020
Full Text
View/download PDF

32. Schistosoma haematobium infection and environmental factors in Southwestern Tanzania: A cross-sectional, population-based study

Author

Manz, Kirsi M., primary, Kroidl, Inge, additional, Clowes, Petra, additional, Gerhardt, Martina, additional, Nyembe, Wilbrod, additional, Maganga, Lucas, additional, Assisya, Weston, additional, Ntinginya, Nyanda E., additional, Berger, Ursula, additional, Hoelscher, Michael, additional, and Saathoff, Elmar, additional

Published
2020
Full Text
View/download PDF

35. Molecular bacterial load assay (MBLA) concurs with culture on the NaOH-induced Mycobacterium tuberculosis loss of viability

Author

Mtafya, Bariki, Sabiiti, Wilber, Sabi, Issa, John, Joseph, Sichone, Emanuel, Ntinginya, Nyanda E., Gillespie, Stephen H., University of St Andrews. School of Medicine, University of St Andrews. Infection and Global Health Division, University of St Andrews. Sir James Mackenzie Institute for Early Diagnosis, University of St Andrews. Centre for Biophotonics, University of St Andrews. Global Health Implementation Group, University of St Andrews. Gillespie Group, University of St Andrews. Infection Group, and University of St Andrews. Biomedical Sciences Research Complex

Subjects
SDG 3 - Good Health and Well-being, RA0421, RA0421 Public health. Hygiene. Preventive Medicine, NDAS, QR Microbiology, QR
Abstract

This work was supported by the commonwealth studentship award for Bariki Mtafya at University of St Andrews in UK and European and Developing Countries Clinical Trials Partnership (EDCTP) through TWENDE and PanACEA II grants. Effective methods to detect viable Mycobacterium tuberculosis (Mtb), the main causative agent of tuberculosis (TB) are urgently needed. To date, cultivation of Mtb is the gold standard which depends on initial sample processing with N-Acetyl-L-Cysteine/Sodium hydroxide (NALC/NaOH), chemicals that compromise Mtb viability and, consequently the performance of downstream tests. We applied culture and the novel Molecular bacterial load assay (MBLA) to measure the loss of Mtb viability following NALC/NaOH treatment of Mtb H37Rv pure culture and clinical sputa from pulmonary TB patients. Compared to untreated controls, NALC/NaOH treatment of Mtb, reduced MBLA detectable bacillary load (estimated colony forming units/milliliter (eCFU/mL) by 0.66±0.21log10- at 23°C (P=0.018) and 0.72±0.08log10- at 30°C (P=0.013). Likewise, NALC/NaOH treatment reduced viable count on solid culture by 0.84±0.02log10- at 23°C (P

Published
2019

37. Phenotypic changes on Mycobacterium tuberculosis-specific CD4 T cells as surrogate markers for tuberculosis treatment efficacy

Author

Ahmed, Mohamed I. M., Ntinginya, Nyanda E., Kibiki, Gibson, Mtafya, Bariki A, Semvua, Hadija, Mpagama, Stellah, Mtabho, Charles, Saathoff, Elmar, Held, Kathrin, Loose, Rebecca, Kroidl, Inge, Chachage, Mkunde, Both, Ulrich von, Haule, Antelmo, Mekota, Anna-Maria, Boeree, Martin J., Gillespie, Stephen H., Hoelscher, Michael, Heinrich, Norbert, Geldmacher, Christof, Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA), University of St Andrews. School of Medicine, University of St Andrews. Infection and Global Health Division, University of St Andrews. Global Health Implementation Group, University of St Andrews. Gillespie Group, University of St Andrews. Biomedical Sciences Research Complex, and University of St Andrews. Infection Group

Subjects
SDG 3 - Good Health and Well-being, Treatment monitoring, QR180, Tuberculosis, DAS, Mycobacterium tuberculosis-specific T cells, Biomarker, QR180 Immunology, Serial sputum culture, TAM-TB assay
Abstract

This work was supported by the European & Developing Countries Clinical Trials Partnership (EDCTP) (PanACEA, grant numbers IP.2007.32011.011, IP.2007.32011.012, IP.2007.32011.013), by the German Ministry for Education and Research (BMBF; Grant No. 01KA0901) by the European Commission, DG XII, INCO-DC (grant ICA-CT-2002-10048) and by the German Center for Infection Research (DZIF). Background: The analysis of phenotypic characteristics on Mycobacterium tuberculosis (MTB)-specific T cells is a promising approach for the diagnosis of active tuberculosis (aTB) and for monitoring treatment success. We therefore studied phenotypic changes on MTB-specific CD4 T cells upon anti-tuberculosis treatment initiation in relation to the treatment response as determined by sputum culture. Methods: Peripheral blood mononuclear cells from subjects with latent MTB infection (n=16) and aTB (n=39) at baseline, week 9, 12 and 26 (end of treatment) were analyzed after intracellular interferon gamma staining and overnight stimulation with tuberculin. Liquid sputum cultures were performed weekly until week 12 and during 4 visits until week 26. Results: T cell activation marker expression on MTB-specific CD4 T cells differed significantly between subjects with aTB and latent MTB infection with no overlap for the frequencies of CD38pos and Ki67pos cells (both p < 0.0001). At 9 weeks after anti-TB treatment initiation the frequencies of activation marker (CD38, HLA-DR, Ki67) positive MTB-specific, but not total CD4 T cells, were significantly reduced (p < 0.0001). Treatment induced phenotypic changes from baseline until week 9 and until week 12 differed substantially between individual aTB patients and correlated with an individual's time to stable sputum culture conversion for expression of CD38 and HLA-DR (both p < 0.05). In contrast, the frequencies of maturation marker CD27 positive MTB-specific CD4 T cells remained largely unchanged until week 26 and significantly differed between subjects with treated TB disease and latent MTB infection (p = 0.0003). Discussion: Phenotypic changes of MTB-specific T cells are potential surrogate markers for tuberculosis treatment efficacy and can help to discriminate between aTB (profile: CD38pos, CD27low), treated TB (CD38neg, CD27low), and latent MTB infection (CD38neg, CD27high). Publisher PDF

Published
2018

38. Wuchereria bancrofti infection is linked to systemic activation of CD4 and CD8 T cells

Author

Kroidl, Inge, primary, Chachage, Mkunde, additional, Mnkai, Jonathan, additional, Nsojo, Anthony, additional, Berninghoff, Myrna, additional, Verweij, Jaco J., additional, Maganga, Lucas, additional, Ntinginya, Nyanda E., additional, Maboko, Leonard, additional, Clowes, Petra, additional, Hoelscher, Michael, additional, Saathoff, Elmar, additional, and Geldmacher, Christof, additional

Published
2019
Full Text
View/download PDF

41. OC 8561 RAPAED TB: AN INNOVATIVE CHILD TB DIAGNOSTIC VALIDATION STUDY

Author

Olbrich, Laura, primary, Zar, Heather, additional, Graham, Steve, additional, Sabi, Issa, additional, Ntinginya, Nyanda E, additional, Bhatt, Nilesh, additional, Nliwasa, Marriott, additional, Corbett, Elizabeth, additional, Song, Rinn, additional, Denkinger, Claudia, additional, Hölscher, Michael, additional, and Heinrich, Norbert, additional

Published
2019
Full Text
View/download PDF

42. OC 8713 MAXIMISING RESEARCH IMPACT TO STRENGTHEN PUBLIC HEALTHCARE

Author

Sabiiti, Wilber, primary, Ntinginya, Nyanda E, additional, Msoka, Elizabeth Fb, additional, Orina, Fred, additional, Mwebaza, Ivan, additional, Mwanyonga, Simeon, additional, Miheso, Barbara, additional, Sanga, Erica, additional, Liyoyo, Aliphonce, additional, Meme, Helen, additional, Mmbaga, Blandina T, additional, Chirnside, Ewan, additional, Joloba, Moses, additional, Amukoye, Evans, additional, Okwera, Alphonse, additional, Kibiki, Gibson S, additional, Gillespie, Stephen H, additional, Mwebaza, Wilber, additional, and Msoka, Nyanda E, additional

Published
2019
Full Text
View/download PDF

43. OC 8215 DIAGNOSTIC ACCURACY OF XPERT MTB/RIF ULTRA FOR PULMONARY TUBERCULOSIS IN CHILDREN: A MULTICENTRE COMPARATIVE STUDY

Author

Sabi, Issa, primary, Rachow, Andrea, additional, Mapamba, Daniel, additional, Clowes, Petra, additional, Ntinginya, Nyanda E, additional, Sasamalo, Mohamed, additional, Kamwela, Lujeko, additional, Haraka, Frederick, additional, Hoelscher, Michael, additional, Paris, Daniel, additional, Saathoff, Elmar, additional, and Reither, Klaus, additional

Published
2019
Full Text
View/download PDF

44. Xpert MTB/RIF Ultra assay for the diagnosis of pulmonary tuberculosis in children: a multicentre comparative accuracy study

Author

Sabi, Issa, primary, Rachow, Andrea, additional, Mapamba, Daniel, additional, Clowes, Petra, additional, Ntinginya, Nyanda E., additional, Sasamalo, Mohamed, additional, Kamwela, Lujeko, additional, Haraka, Frederick, additional, Hoelscher, Michael, additional, Paris, Daniel H., additional, Saathoff, Elmar, additional, and Reither, Klaus, additional

Published
2018
Full Text
View/download PDF

45. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

Author

Boeree, Martin J., Heinrich, Norbert, Aarnoutse, Rob, Diacon, Andreas H., Dawson, Rodney, Rehal, Sunita, Kibiki, Gibson S., Churchyard, Gavin, Sanne, Ian, Ntinginya, Nyanda E., Minja, Lilian T., Hunt, Robert D., Charalambous, Salome, Hanekom, Madeleine, Semvua, Hadija H., Mpagama, Stellah G., Manyama, Christina, Mtafya, Bariki, Reither, Klaus, Wallis, Robert S., Venter, Amour, Narunsky, Kim, Mekota, Anka, Henne, Sonja, Colbers, Angela, Plemper van Balen, Georgette, Gillespie, Stephen H., Phillips, Patrick P. J., Hoelscher, Michael, PanACEA Consortium, University of St Andrews. School of Medicine, University of St Andrews. Global Health Implementation Group, University of St Andrews. Gillespie Group, University of St Andrews. Biomedical Sciences Research Complex, University of St Andrews. Infection Group, and University of St Andrews. Infection and Global Health Division

Subjects
SDG 3 - Good Health and Well-being, RA0421, RA0421 Public health. Hygiene. Preventive Medicine, ~DC~, NDAS, BDC, bacterial infections and mycoses, R2C
Abstract

The study was funded by the European and Developing Countries Clinical Trials partnership (EDCTP), the German Ministry for Education and Research (BmBF), and the Medical Research Council UK (MRC). Background. Tuberculosis is the world's leading infectious disease killer. We aimed to identify shorter, safer drug regimens for the treatment of tuberculosis. Methods. We did a randomised controlled, open-label trial with a multi-arm, multi-stage design. The trial was done in seven sites in South Africa and Tanzania, including hospitals, health centres, and clinical trial centres. Patients with newly diagnosed, rifampicin-sensitive, previously untreated pulmonary tuberculosis were randomly assigned in a 1:1:1:1:2 ratio to receive (all orally) either 35 mg/kg rifampicin per day with 15–20 mg/kg ethambutol, 20 mg/kg rifampicin per day with 400 mg moxifloxacin, 20 mg/kg rifampicin per day with 300 mg SQ109, 10 mg/kg rifampicin per day with 300 mg SQ109, or a daily standard control regimen (10 mg/kg rifampicin, 5 mg/kg isoniazid, 25 mg/kg pyrazinamide, and 15–20 mg/kg ethambutol). Experimental treatments were given with oral 5 mg/kg isoniazid and 25 mg/kg pyrazinamide per day for 12 weeks, followed by 14 weeks of 5 mg/kg isoniazid and 10 mg/kg rifampicin per day. Because of the orange discoloration of body fluids with higher doses of rifampicin it was not possible to mask patients and clinicians to treatment allocation. The primary endpoint was time to culture conversion in liquid media within 12 weeks. Patients without evidence of rifampicin resistance on phenotypic test who took at least one dose of study treatment and had one positive culture on liquid or solid media before or within the first 2 weeks of treatment were included in the primary analysis (modified intention to treat). Time-to-event data were analysed using a Cox proportional-hazards regression model and adjusted for minimisation variables. The proportional hazard assumption was tested using Schoelfeld residuals, with threshold p

Published
2016

46. Phenotypic Changes on Mycobacterium Tuberculosis-Specific CD4 T Cells as Surrogate Markers for Tuberculosis Treatment Efficacy

Author

Ahmed, Mohamed I. M., primary, Ntinginya, Nyanda E., additional, Kibiki, Gibson, additional, Mtafya, Bariki A, additional, Semvua, Hadija, additional, Mpagama, Stellah, additional, Mtabho, Charles, additional, Saathoff, Elmar, additional, Held, Kathrin, additional, Loose, Rebecca, additional, Kroidl, Inge, additional, Chachage, Mkunde, additional, Both, Ulrich von, additional, Haule, Antelmo, additional, Mekota, Anna-Maria, additional, Boeree, Martin J., additional, Gillespie, Stephen H., additional, Hoelscher, Michael, additional, Heinrich, Norbert, additional, and Geldmacher, Christof, additional

Published
2018
Full Text
View/download PDF

48. Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages

Author

Stucki, David, primary, Brites, Daniela, additional, Jeljeli, Leïla, additional, Coscolla, Mireia, additional, Liu, Qingyun, additional, Trauner, Andrej, additional, Fenner, Lukas, additional, Rutaihwa, Liliana, additional, Borrell, Sonia, additional, Luo, Tao, additional, Gao, Qian, additional, Kato-Maeda, Midori, additional, Ballif, Marie, additional, Egger, Matthias, additional, Macedo, Rita, additional, Mardassi, Helmi, additional, Moreno, Milagros, additional, Vilanova, Griselda Tudo, additional, Fyfe, Janet, additional, Globan, Maria, additional, Thomas, Jackson, additional, Jamieson, Frances, additional, Guthrie, Jennifer L, additional, Asante-Poku, Adwoa, additional, Yeboah-Manu, Dorothy, additional, Wampande, Eddie, additional, Ssengooba, Willy, additional, Joloba, Moses, additional, Boom, W Henry, additional, Basu, Indira, additional, Bower, James, additional, Saraiva, Margarida, additional, Vasconcellos, Sidra E G, additional, Suffys, Philip, additional, Koch, Anastasia, additional, Wilkinson, Robert, additional, Gail-Bekker, Linda, additional, Malla, Bijaya, additional, Ley, Serej D, additional, Beck, Hans-Peter, additional, de Jong, Bouke C, additional, Toit, Kadri, additional, Sanchez-Padilla, Elisabeth, additional, Bonnet, Maryline, additional, Gil-Brusola, Ana, additional, Frank, Matthias, additional, Penlap Beng, Veronique N, additional, Eisenach, Kathleen, additional, Alani, Issam, additional, Ndung'u, Perpetual Wangui, additional, Revathi, Gunturu, additional, Gehre, Florian, additional, Akter, Suriya, additional, Ntoumi, Francine, additional, Stewart-Isherwood, Lynsey, additional, Ntinginya, Nyanda E, additional, Rachow, Andrea, additional, Hoelscher, Michael, additional, Cirillo, Daniela Maria, additional, Skenders, Girts, additional, Hoffner, Sven, additional, Bakonyte, Daiva, additional, Stakenas, Petras, additional, Diel, Roland, additional, Crudu, Valeriu, additional, Moldovan, Olga, additional, Al-Hajoj, Sahal, additional, Otero, Larissa, additional, Barletta, Francesca, additional, Carter, E Jane, additional, Diero, Lameck, additional, Supply, Philip, additional, Comas, Iñaki, additional, Niemann, Stefan, additional, and Gagneux, Sebastien, additional

Published
2016
Full Text
View/download PDF

49. Limited value of whole blood Xpert® MTB/RIF for diagnosing tuberculosis in children

Author

Pohl, Christian, primary, Rutaihwa, Liliana K., additional, Haraka, Frederick, additional, Nsubuga, Martin, additional, Aloi, Francesco, additional, Ntinginya, Nyanda E., additional, Mapamba, Daniel, additional, Heinrich, Norbert, additional, Hoelscher, Michael, additional, Marais, Ben J., additional, Jugheli, Levan, additional, and Reither, Klaus, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results